Literature DB >> 3741726

The influence of enzyme induction on polymorphic sparteine oxidation.

M Eichelbaum, S Mineshita, E E Ohnhaus, C Zekorn.   

Abstract

The effects of antipyrine (1200 mg day-1), phenobarbitone (100 mg day-1) and rifampicin (600 mg and 1200 mg day-1, respectively) administration for 7 days on sparteine metabolism and 6 beta-hydroxycortisol excretion were studied in panels of extensive (EM) and poor metaboliser (PM) subjects. Drug metabolism was induced in both EM and PM subjects by antipyrine and rifampicin pretreatment as indicated by increased excretion of 6 beta-hydroxycortisol. A 30% increase in metabolic clearance of sparteine was observed in EM subjects following rifampicin administration whereas in PM subjects no effect on the overall elimination of the drug was seen. The data indicate that the regulation of cytochrome P-450 isozyme involved in polymorphic debrisoquine/sparteine metabolism is predominantly under genetic control and that enzyme induction exerts only a marginal effect.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3741726      PMCID: PMC1401070          DOI: 10.1111/j.1365-2125.1986.tb02879.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

Review 1.  Genetic and environmental factors affecting drug disposition in man.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

2.  [Polymorphisms and deficient drug metabolism as triggers of toxic reactions (author's transl)].

Authors:  H J Dengler; M Eichelbaum
Journal:  Arzneimittelforschung       Date:  1977

3.  Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man.

Authors:  E E Ohnhaus; E Gerber-Taras; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  6 beta-hydroxycortisol excretion in relation to polymorphic N-oxidation of sparteine.

Authors:  B K Park; M Eichelbaum; E E Ohnhaus
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 6.  Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

7.  The effect of enzyme induction on diazepam metabolism in man.

Authors:  E E Ohnhaus; B K Park; J P Colombo; P Heizmann
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

8.  Enzyme induction and renal function in man.

Authors:  E E Ohnhaus; J Martin; J Kinser; J P Colombo
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

9.  Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.

Authors:  J P Miguet; P Mavier; C J Soussy; D Dhumeaux
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more
  34 in total

Review 1.  Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Authors:  Rashmi R Shah
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

2.  Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.

Authors:  A S Gross; G Mikus; C Fischer; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Rifampicin lowers plasma concentrations of propafenone and its antiarrhythmic effect.

Authors:  J M Castel; E Cappiello; D Leopaldi; R Latini
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

Review 4.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

5.  Oxidative polymorphism of debrisoquine in Parkinson's disease.

Authors:  J Benitez; J M Ladero; F J Jimenez-Jimenez; C Martinez; A M Puerto; M J Valdivielso; A Llerena; J Cobaleda; J J Muñoz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

Review 6.  Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.

Authors:  A Llerena; J Cobaleda; C Martínez; J Benítez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 7.  Nature of autoantigens and autoantibodies in autoimmune hepatitis.

Authors:  M P Manns; K H Meyer zum Büschenfelde
Journal:  Springer Semin Immunopathol       Date:  1990

Review 8.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

Review 9.  Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs.

Authors:  P A De Smet; J R Brouwers
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

10.  Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots.

Authors:  P R Jackson; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.